Carl Zeiss Meditec Announces Milestone of 1 Million SMILE Procedures

October 6, 2017: By Jon Swedien
SMILE laser vision correction procedure

SMILE laser vision correction procedure

Carl Zeiss Meditec announced Sept. 28 that doctors performing laser vision correction surgery using the company’s small-incision lenticule extraction (SMILE) technology have now surpassed 1 million procedures worldwide.

SMILE is being performed regularly by more than 1,300 surgeons in over 65 countries, Zeiss said.

A flapless procedure, SMILE requires only one laser to perform the treatment. During SMILE, doctors correct patients’ refractive errors using the VisuMax femtosecond laser. With the laser, surgeons create a thin disc-shaped lenticule within the cornea, which is then removed through a small incision on the surface of the cornea, also created by the laser, thereby achieving the desired vision correction.

Because the procedure requires only a small incision, it leaves the outer corneal layer largely intact, thus potentially contributing to the cornea’s stability (both biomechanical and refractive) after surgery and to fast visual recovery, Zeiss said.

The company is based in Jena, Germany.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Offers Compounded Alternative to Restasis for Dry Eye

US District Court Invalidates Four Restasis Patents

BioTime Prices $25 Million Public Offering of Common Stock

Gemini Completes $42.5 Million Series A Financing for Dry AMD Treatment

BIOPHYTIS Raises €10.4 Million to Develop Anti-Aging Drugs, One for Dry AMD

Amydis Receives $530 Thousand NIH Award to Advance Ophthalmic Diagnostic Probes

Realm Announces Completion of $26 million Private Placement

Sight Sciences Secures $10 Million in Oversubscribed Series C Financing

Aerpio Names Stephen Hoffman CEO; Founder Joseph Gardner Remains President

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022